This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including Ac, Bi, Ra, Pb, Th, Ra, At, and Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824049 | PMC |
http://dx.doi.org/10.3390/pharmaceutics13010049 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!